Recently completed and ongoing studies involving anticoagulants
| Study title . | Clinical trials #/Phase . | Intervention . | Status . | Primary sponsor . |
|---|---|---|---|---|
| An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease | NCT01036802 Phase 2 | Warfarin | Terminated | Univ. of North Carolina-Chapel Hill |
| Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo | NCT01419977 Phase 2 | Dalteparin | Completed | Duke Univ. |
| Unfractionated Heparin in Acute Chest Syndrome: A Pilot Feasibility Randomized Controlled Trial of Unfractionated Heparin vs Standard of Care in Acute Chest Syndrome | NCT02098993 Phase 2 | Unfractionated heparin | Recruiting | Univ. of Pittsburgh |
| The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease | NCT02072668 Phase 2 | Rivaroxiban | Recruiting | Univ. of North Carolina-Chapel Hill |
| Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease | NCT02179177 Phase 2 | Apixiban | Recruiting | Duke Univ. |
| A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease | NCT01800526 Phase 0 | N-acetyl cysteine | Recruiting | Puget Sound Blood Center |
| Study title . | Clinical trials #/Phase . | Intervention . | Status . | Primary sponsor . |
|---|---|---|---|---|
| An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease | NCT01036802 Phase 2 | Warfarin | Terminated | Univ. of North Carolina-Chapel Hill |
| Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo | NCT01419977 Phase 2 | Dalteparin | Completed | Duke Univ. |
| Unfractionated Heparin in Acute Chest Syndrome: A Pilot Feasibility Randomized Controlled Trial of Unfractionated Heparin vs Standard of Care in Acute Chest Syndrome | NCT02098993 Phase 2 | Unfractionated heparin | Recruiting | Univ. of Pittsburgh |
| The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease | NCT02072668 Phase 2 | Rivaroxiban | Recruiting | Univ. of North Carolina-Chapel Hill |
| Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease | NCT02179177 Phase 2 | Apixiban | Recruiting | Duke Univ. |
| A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease | NCT01800526 Phase 0 | N-acetyl cysteine | Recruiting | Puget Sound Blood Center |